Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:deferasirox
|
| gptkbp:approvalYear |
2005
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:V03AC03
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to deferasirox |
| gptkbp:form |
tablet for oral suspension
|
| https://www.w3.org/2000/01/rdf-schema#label |
Exjade
|
| gptkbp:indication |
gptkb:non-transfusion-dependent_thalassemia
transfusional iron overload |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain skin rash increased serum creatinine |
| gptkbp:usedFor |
treatment of chronic iron overload
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|